Compare Dishman Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PANACEA BIOTECH - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PANACEA BIOTECH DISHMAN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 25.1 12.1 207.1% View Chart
P/BV x 3.3 2.9 115.0% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PANACEA BIOTECH
Mar-18
DISHMAN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs374364 102.9%   
Low Rs129129 99.8%   
Sales per share (Unadj.) Rs197.896.8 204.4%  
Earnings per share (Unadj.) Rs21.2-12.4 -170.9%  
Cash flow per share (Unadj.) Rs34.7-2.9 -1,217.3%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.950.4 356.9%  
Shares outstanding (eoy) m80.6961.25 131.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.5 49.9%   
Avg P/E ratio x11.9-19.9 -59.7%  
P/CF ratio (eoy) x7.2-86.4 -8.4%  
Price / Book Value ratio x1.44.9 28.6%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30615,101 134.5%   
No. of employees `0000.82.5 33.6%   
Total wages/salary Rs m5,3551,516 353.2%   
Avg. sales/employee Rs Th19,252.72,401.9 801.6%   
Avg. wages/employee Rs Th6,459.5614.2 1,051.7%   
Avg. net profit/employee Rs Th2,064.1-307.9 -670.3%   
INCOME DATA
Net Sales Rs m15,9615,928 269.2%  
Other income Rs m26582 322.5%   
Total revenues Rs m16,2266,010 270.0%   
Gross profit Rs m4,103845 485.4%  
Depreciation Rs m1,091585 186.3%   
Interest Rs m9441,006 93.9%   
Profit before tax Rs m2,334-664 -351.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m12 52.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62499 632.5%   
Profit after tax Rs m1,711-760 -225.1%  
Gross profit margin %25.714.3 180.3%  
Effective tax rate %26.7-14.9 -179.8%   
Net profit margin %10.7-12.8 -83.6%  
BALANCE SHEET DATA
Current assets Rs m11,0185,603 196.6%   
Current liabilities Rs m9,5176,910 137.7%   
Net working cap to sales %9.4-22.0 -42.7%  
Current ratio x1.20.8 142.8%  
Inventory Days Days110206 53.7%  
Debtors Days Days3584 41.6%  
Net fixed assets Rs m16,3049,941 164.0%   
Share capital Rs m16161 263.3%   
"Free" reserves Rs m12,9073,026 426.6%   
Net worth Rs m14,5163,087 470.2%   
Long term debt Rs m4,1895,707 73.4%   
Total assets Rs m29,80516,076 185.4%  
Interest coverage x3.50.3 1,019.9%   
Debt to equity ratio x0.31.8 15.6%  
Sales to assets ratio x0.50.4 145.2%   
Return on assets %8.91.5 582.7%  
Return on equity %11.8-24.6 -47.9%  
Return on capital %17.53.9 447.6%  
Exports to sales %24.824.0 103.2%   
Imports to sales %3.717.5 21.3%   
Exports (fob) Rs m3,9561,424 277.8%   
Imports (cif) Rs m5961,040 57.3%   
Fx inflow Rs m4,9521,600 309.5%   
Fx outflow Rs m6971,131 61.6%   
Net fx Rs m4,255469 908.0%   
CASH FLOW
From Operations Rs m2,7861,180 236.1%  
From Investments Rs m-1,529553 -276.5%  
From Financial Activity Rs m-941-1,644 57.3%  
Net Cashflow Rs m31690 352.7%  

Share Holding

Indian Promoters % 61.4 74.5 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.6 616.7%  
FIIs % 12.7 1.3 976.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 23.6 93.6%  
Shareholders   46,261 10,259 450.9%  
Pledged promoter(s) holding % 35.8 35.1 102.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - AJANTA PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS